The aim of the study is to evaluate the long‑term safety of the medicine and to see if it can help increase height. Participants will take the capsule each day and attend regular visits where doctors check vital signs, perform blood tests, eye and dental exams, and take simple scans such as X‑rays and a bone‑density scan called dual x‑ray absorptiometry to monitor growth. Height will be measured over time and compared with standard growth charts.

The purpose of this research is to determine if vosoritide is safe and effective in improving growth in infants and young children with hypochondroplasia who are less than 3 years old. The study will compare the effects of vosoritide against a placebo. During the study, participants will receive daily injections of either vosoritide or placebo for 52 weeks (one year).

Throughout the study, doctors will monitor the children’s growth, measure changes in their height, and check their overall health and safety. They will also look at how the medication affects bone development using special DXA scans (a type of low-dose X-ray that measures bone density). The medication will be given through subcutaneous injections, which means the medicine is injected just under the skin.

The purpose of this study is to look at the long-term safety and effectiveness of vosoritide treatment in children with hypochondroplasia until they reach their final adult height. This study is designed for children who have already been taking part in previous studies of this medication and still have open growth plates in their bones, which means they are still growing. The study will continue for many years, following participants as they grow, to see how the treatment affects their height over time and to watch for any side effects that may occur.

During the study, participants will receive daily injections of vosoritide, which will be given by their parent or caregiver after proper training. The study will measure changes in height and compare these measurements to standard growth charts to see if the treatment is helping children grow taller. Regular visits will be scheduled to check on the participants’ growth, overall health, and any side effects from the medication. The treatment will continue until participants reach their final adult height, which is when their bones stop growing.

The purpose of this research is to evaluate how effective and safe infigratinib is for treating children with hypochondroplasia. The study has two parts – an initial open-label phase followed by a double-blind, randomized, placebo-controlled phase. During the study, researchers will measure changes in height velocity (how quickly children grow), height in relation to others with the same condition, and body proportions.

Children participating in the study will need to take oral medication and attend scheduled study visits. The study includes children of different age groups (from 3 to under 18 years old) and requires that participants have already been part of an observational study for at least 26 weeks prior to starting this treatment study.

The purpose of the study is to assess how effective and safe Vosoritide is in increasing the growth rate in children with Hypochondroplasia. Participants in the study will be randomly assigned to receive either Vosoritide or a placebo, which is a substance with no active medication. The study will last for about one year, during which the growth of the children will be monitored and compared to their growth before starting the treatment.

Throughout the study, the main focus will be on changes in the children’s growth rate and height. The study aims to provide valuable information on whether Vosoritide can help children with Hypochondroplasia grow taller over time. This research is important for understanding potential new treatments for this condition and improving the quality of life for those affected.